In 2023, the emerging cancer diagnostics market is estimated to be valued at over $23 billion. Everything is fair game…
Precision diagnostics company INOVIQ (ASX: IIQ) has achieved noteworthy results from an independent clinical validation study of its SubB2M/CA15-3 test…